Physician profile
Shannon B Standish
NPI 1013494970
$1,469.13
in general payments reported to CMS, 2019-2025
14 companies · $53.88 in 2025
The $53.88 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $633 · 2022: $390 · 2023: $266 · 2024: $127 · 2025: $53.88.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $388.02 | 2021-2024 | Farxiga |
| Mallinckrodt Hospital Products INC. | $235.27 | 2021-2022 | |
| Vifor Pharma, INC. | $220.73 | 2021-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $160.19 | 2021-2023 | Arexvy, Benlysta |
| Bayer Healthcare Pharmaceuticals INC. | $119.01 | 2021-2022 | |
| Akebia Therapeutics INC | $81.51 | 2021-2025 | Vafseo, Auryxia |
| Opko Pharmaceuticals, LLC | $58.87 | 2021 | |
| Calliditas Therapeutics US INC. | $57.29 | 2022-2023 | Tarpeyo |
| Amgen INC. | $35.03 | 2022 | |
| Fresenius USA Marketing, INC. | $24.65 | 2024 | Velphoro |
| Daiichi Sankyo INC. | $23.40 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.54 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.43 | 2021 | |
| Ani Pharmaceuticals, INC. | $20.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Standish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.